Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA-Twist-TRICOM
- Development stage
- Preclinical
- Lead developer
- Bavarian Nordic
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
MVA-Twist-TRICOM (also known as MVA-TWIST/TRICOM) is a recombinant viral vector-based therapeutic cancer vaccine developed by Bavarian Nordic in collaboration with the National Cancer Institute (NCI). The vaccine utilizes a Modified Vaccinia Ankara (MVA) virus vector to deliver the transgene for Twist-related protein 1 (TWIST1), a transcription factor highly expressed in metastatic tumor cells that drives epithelial-to-mesenchymal transition (EMT). Additionally, the vaccine incorporates TRICOM, a triad of T-cell costimulatory molecules consisting of B7-1 (CD80), ICAM-1 (CD54), and LFA-3 (CD58). By expressing both the Twist antigen and costimulatory molecules, MVA-Twist-TRICOM converts infected cells into competent antigen-presenting cells, thereby inducing robust antigen-specific CD4+ and CD8+ T-cell immune responses to target and eliminate metastatic cancer cells.
- Other names
- MVA-TWIST-TRICOMMVA-TWIST/TRICOM
02
Targets
CD58 (Leukocyte function-associated antigen 3)CD80 (T-lymphocyte activation antigen CD80)TWIST1ICAM1 (Intercellular Adhesion Molecule 1)
Beyond the preview
Go deeper on MVA-Twist-TRICOM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA-Twist-TRICOM.